The European Medicines Agency has directed sponsors of new and existing biological medicines to review their products for the presence of possible nitrosamine impurities, as is already required for medicines containing chemically synthesized active substances.
In addition, all drug sponsors are being asked to initiate new measures – such as developing appropriate control strategies and...